Drug intelligence / Profile preview

OGB21504

Development stage: Preclinical
Lead developer: OnceGene
Modality: Recombinant Proteins and Enzymes

Overview

OGB21504 is a multi-target drug candidate developed by ONEGENE for the treatment of fibrotic diseases. It is engineered using the proprietary UniStac (Universal Stabilized Trimerization and C-terminal fusion) platform, which is designed to create multi-specific protein therapeutics. OGB21504 is intended to simultaneously modulate three undisclosed biological targets involved in the pathogenesis of fibrosis. The candidate is currently in the preclinical stage of development, aiming to provide a more comprehensive therapeutic effect than single-target agents in complex fibrotic conditions.

Beyond the preview

Go deeper on OGB21504.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OGB21504.

Explore the full profile